Investigation of methylation patterns of SFRP1, SFRP2, SHP1, SOCS3, EBF2 genes before and after treatment in acute myeloid leukemia and chronic myeloid leukemia

50th European-Society-of-Human-Genetics (ESHG) Conference -- MAY 27-30, 2017 -- Copenhagen, DENMARKWOS: 000489312606241[No abstract available]European Soc Human Gene

A broad range of symptoms in allgrove syndrome: single center experience in Southeast Anatolia

PMID = 3143588

A prospective randomized controlled trial to determine if cryotherapy can reduce the pain of patients with minor form of recurrent aphthous stomatitis

PubMed: 16360599Background. Tissue cooling has long been used in the management of both acute and chronic pain. Objective. To determine whether the application of cryotherapy can reduce the pain of patients with minor form of recurrent aphthous stomatitis.Study design. Twenty adult patients who had 2 discrete aphthous stomatitides in the labial mucosa at the same time were included in this prospective, randomized, and placebo-controlled study. One of the 2 aphthous stomatitides was treated with cryotherapy, the other serving as a control. The pain of aphthous stomatitis was scored by the patient on a 6-point scale (from 0 to 5). The size of the aphthous stomatitis was also measured. Results. At any interval, no statistical difference was found between the cryotherapy-treated aphthous stomatitis and the control in the change in the value of pain severity, nor was any statistical difference found in the change in the size of the aphthous stomatitis. However, a trend toward less pain in the aphthous stomatitis receiving cryotherapy was noted. Conclusion. These results suggest that application of cryotherapy on minor form of recurrent oral aphthous stomatitis has no benefecial analgesic effect compared to placebo. © 2006 Mosby, Inc. All rights reserved

The Efficacy of Intermittant Low-Dose Systemic Corticosteroid in the Treatment of Alopecia Areata

Alopecia areata (AA) is a common cause of non-scarring alopecia characterized by patchy hair loss. AA is difficult to treat because of its chronic and inflammatory nature. The aim of the present study was to investigate the effect of low-dose systemic corticosteroids in the treatment of AA. Fifteen patients with AA were included in this study. Systemic prednisolone 10-15 mg/day on 2 consecutive days per week for 6 months was administered. Fourteen patients (93.3%) had patchy alopecia areata. One patient (6.3%) had alopecia universalis. Seven (46.7%) patients showed complete healing, 5 (33.3%) showed partial response and 3 (20%) did not respond to treatment. Low-dose intermittant corticosteroid therapy may be a successful and well tolerated treatment option in AA and also in patients with alopecia totalis and universalis

What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?

PubMedID: 30270069Background and aims: Familial hypercholesterolemia (FH) is a common genetic disease of high-level cholesterol leading to premature atherosclerosis. One of the key aspects to overcome FH burden is the generation of large-scale reliable data in terms of registries. This manuscript underlines the important results of nation-wide Turkish FH registries (A-HIT1 and A-HIT2). Methods: A-HIT1 is a survey of homozygous FH patients undergoing low density lipoprotein (LDL) apheresis (LA). A-HIT2 is a registry of adult FH patients (homozygous and heterozygous) admitted to outpatient clinics. Both registries used clinical diagnosis of FH. Results: A-HIT1 evaluated 88 patients (27 ± 11 years, 41 women) in 19 centers. All patients were receiving regular LA. There was a 7.37 ± 7.1-year delay between diagnosis and initiation of LA. LDL-cholesterol levels reached the target only in 5 cases. Mean frequency of apheresis sessions was 19 ± 13 days. None of the centers had a standardized approach for LA. Mean frequency of apheresis sessions was every 19 ± 13 (7–90) days. Only 2 centers were aware of the target LDL levels. A–HIT2 enrolled 1071 FH patients (53 ± 8 years, 606 women) from 31 outpatients clinics specialized in cardiology (27), internal medicine (1), and endocrinology (3); 96.4% were heterozygous. 459 patients were on statin treatment. LDL targets were attained in 23 patients (2.1% of the whole population, 5% receiving statin) on treatment. However, 66% of statin-receiving patients were on intense doses of statins. Awareness of FH was 9.5% in the whole patient population. Conclusions: The first nationwide FH registries revealed that FH is still undertreated even in specialized centers in Turkey. Additional effective treatment regiments are urgently needed. © 2018 Elsevier B.V.Sanofi Pfizer AmgenA-HIT1 and 2 registries are sponsored by the Turkish Society of Cardiology that receives funding from a variety of sources (including unrestricted research grants from Aegerion, Amyrit, Amgen, Pfizer, and Sanofi). Appendix